access to national-level pharmaceutical sales data and International level sales data to estimate and forecast trends in pharmaceutical sales, pricing, and volume of distribution throughout various settings of care.
Closed Solicitation Posted
- Solicitation number
- 75F40122R00082
- Agency
-
Center for Drug Evaluation and Research
Food and Drug Administration, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 518210 Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services
- Place of performance
- Silver Spring, Maryland 20903, United States
Notice details come from SAM.gov. Updated .
About this opportunity
The Food and Drug Administration's Center for Drug Evaluation and Research is soliciting proposals to provide ongoing access to national and international pharmaceutical sales data to estimate trends in drug sales, pricing, volume of distribution, and support regulatory decision making. Offerors must propose pricing to license sales data and provide custom reporting/analysis for domestic and international markets. Proposals will be evaluated based on data quality, reporting capabilities, and pricing. The base period of performance is one year with four one-year option periods, with proposals due by August 30th, 2022 and anticipated award by September 29th, 2022.
There is no set-aside designation. The primary NAICS code is 541715 and PSC code R699. The place of performance is Silver Spring, Maryland. Offerors must provide unlimited user access and quarterly data updates for the base year and optional periods. Labor categories include Project Manager, Data Analysts, and Pharmacists to support unlimited analysis and custom reporting of national and international sales trends over the five-year contract.
Notice text
2 versions
Update #2 · Latest ·
FDA/CDER requires access to national-level pharmaceutical sales data and international-level pharmaceutical sales data to estimate and forecast trends in pharmaceutical sales, pricing, and volume of distribution throughout various settings of care. Continued access to these data allows the FDA to respond expeditiously to questions relating to drug safety, the impact of regulatory policies, and to potential drug shortage situations, helping the Agency to make more informed decisions about matters that affect the health of Americans.
See Attachments for RFP and related attachments.
Modification:
See attachment for Contractor Questions and Government Responses.
Bassed on the Contractor Questions, the Description Title for this requirement has been updated and the Solictation Document has been updated. Please see the document "Solcitation updated 9 1 2022..."
Update #1 ·
FDA/CDER requires access to national-level pharmaceutical sales data to estimate and forecast trends in pharmaceutical sales, pricing, and volume of distribution throughout various settings of care. Continued access to these data allows the FDA to respond expeditiously to questions relating to drug safety, the impact of regulatory policies, and to potential drug shortage situations, helping the Agency to make more informed decisions about matters that affect the health of Americans.
See Attachments for RFP and related attachments.
Files
Show all 11
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Best Pharmaceuticals for Children Act Data Coordination Center | National Institute of Child Health and Human Development | No set-aside | |
| FDA Scientific & Regulatory Support Services(SRS) | FDA Office of Acquisition and Grant Services | Total Small Business | |
| FDA/CDRH Scientific Technical Capacity for Regulatory Review | FDA Office of Acquisition and Grant Services | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity